Literature DB >> 22846732

Genetic testing by cancer site: ovary.

Scott M Weissman1, Shelly M Weiss, Anna C Newlin.   

Abstract

Approximately 1 in every 4 to 5 women with a diagnosis of ovarian cancer has a hereditary gene mutation that is responsible for the development of her cancer. Identifying women at increased risk of developing ovarian cancer due to a hereditary cancer syndrome can allow for early detection or prevention of not only ovarian cancer, but also other cancers, depending on the causative gene. This review focuses on 3 of the most common hereditary ovarian cancer syndromes, hereditary breast and ovarian cancer syndrome (the BRCA1 and BRCA2 genes), Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer syndrome), and Peutz-Jeghers syndrome, including key features, genetics, and management of these syndromes. In addition, newly discovered genes (eg, RAD51C and RAD51D) linked to ovarian cancer are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22846732     DOI: 10.1097/PPO.0b013e31826246c2

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  13 in total

Review 1.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

2.  RNF138 interacts with RAD51D and is required for DNA interstrand crosslink repair and maintaining chromosome integrity.

Authors:  Brian D Yard; Nicole M Reilly; Michael K Bedenbaugh; Douglas L Pittman
Journal:  DNA Repair (Amst)       Date:  2016-04-21

3.  Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.

Authors:  Christopher J LaFargue; Katelyn F Handley; Nicole D Fleming; Alpa M Nick; Anca Chelariu-Raicu; Bryan Fellman; Tara Castellano; Aiko Ogasawara; Marianne Hom-Tedla; Erin A Blake; Alexandre A B A da Costa; Aleia K Crim; Alejandro Rauh-Hain; Shannon N Westin; Robert L Coleman; Koji Matsuo; Glauco Baiocchi; Kosei Hasegawa; Kathleen Moore; Anil K Sood
Journal:  Gynecol Oncol       Date:  2022-02-23       Impact factor: 5.482

4.  Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Authors:  Edward D Esplin; Ling Oei; Michael P Snyder
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

Review 5.  Management of genetic syndromes predisposing to gynecologic cancers.

Authors:  Susan Miesfeldt; Amanda Lamb; Christine Duarte
Journal:  Curr Treat Options Oncol       Date:  2013-03

6.  Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Navya Nair; Cecelia Bellcross; Lisa Haddad; Monique Martin; Roland Matthews; Sheryl Gabram-Mendola; Barbara Crane; Dana Meaney-Delman
Journal:  J Cancer Educ       Date:  2017-03       Impact factor: 2.037

7.  Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.

Authors:  Marketa Janatova; Jana Soukupova; Jana Stribrna; Petra Kleiblova; Michal Vocka; Petra Boudova; Zdenek Kleibl; Petr Pohlreich
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

8.  Integrated analysis of germline and somatic variants in ovarian cancer.

Authors:  Krishna L Kanchi; Kimberly J Johnson; Charles Lu; Michael D McLellan; Mark D M Leiserson; Michael C Wendl; Qunyuan Zhang; Daniel C Koboldt; Mingchao Xie; Cyriac Kandoth; Joshua F McMichael; Matthew A Wyczalkowski; David E Larson; Heather K Schmidt; Christopher A Miller; Robert S Fulton; Paul T Spellman; Elaine R Mardis; Todd E Druley; Timothy A Graubert; Paul J Goodfellow; Benjamin J Raphael; Richard K Wilson; Li Ding
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

9.  The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Authors:  Marie Eliade; Jeremy Skrzypski; Amandine Baurand; Caroline Jacquot; Geoffrey Bertolone; Catherine Loustalot; Charles Coutant; France Guy; Pierre Fumoleau; Yannis Duffourd; Laurent Arnould; Alexandra Delignette; Marie-Martine Padéano; Côme Lepage; Géraldine Raichon-Patru; Axelle Boudrant; Marie-Christine Bône-Lépinoy; Anne-Laure Villing; Aurélie Charpin; Karine Peignaux; Sandy Chevrier; Frédérique Vegran; François Ghiringhelli; Romain Boidot; Nicolas Sevenet; Sarab Lizard; Laurence Faivre
Journal:  Oncotarget       Date:  2017-01-10

Review 10.  The biological effects and clinical implications of BRCA mutations: where do we go from here?

Authors:  Dominique Stoppa-Lyonnet
Journal:  Eur J Hum Genet       Date:  2016-09       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.